Veracyte, Inc.’s Post

New research published in JAMA Network Open highlights the promise of combining genomic analyses with clinical outcome data to support prostate cancer treatment. Utilizing Veracyte's Decipher Prostate Genomic Classifier, this study reviewed over 92,000 patients, showcasing the potential for more personalized and timely treatment strategies. https://lnkd.in/euZERMRh #ProstateCancer #PersonalizedCare

We are pleased to announce that Veracyte’s Afirma Genomic Sequencing Classifier (GSC) now has expanded Medicare coverage for patients with “Bethesda V” thyroid nodules, or those that are suspicious for cancer. This pivotal milestone allows thousands of patients access to advanced technology to help guide their treatment based on the molecular characteristics of their nodules. John Leite, our Chief Commercial Officer, CLIA Business, shares his perspective on this important development for patients and personalized medicine. #Endocrinology #ThyroidCancer

New data published in ESMO Open show that Veracyte’s Prosigna Breast Cancer Assay significantly influenced treatment decisions for nearly one-third of physicians treating patients with early-stage breast cancer. Learn more about the study and how Prosigna can help guide more confident treatment decisions in this article authored by Jenna Lefkowits, our Executive Director for IVD Marketing & Strategy.

New findings derived from Veracyte’s Afirma GRID (Genomic Resource for Intelligent Discovery) tool suggest the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The findings, which could potentially help clinicians further individualize care based on each patient’s tumor biology, were presented today at ENDO 2024. #ENDO2024 #Endocrinology #ThyroidCancer https://lnkd.in/ewGuqB6C

This morning at ASCO 2024: From 9 a.m. – 12 p.m. CDT, don’t miss several poster sessions that demonstrate the capabilities of Veracyte’s Prosigna Breast Cancer Assay and Decipher Bladder Genomic Classifier. Our team looks forward to discussing these presentations with the oncology community - stop by booth 35131 to connect with our experts! #ASCO24 #BreastCancer #BladderCancer

Day 1 at ENDO 2024! Stop by booth 709 to learn more about how our Afirma® Genomic Sequencing Classifier can help you personalize diagnosis and treatment for your patients with thyroid nodules, or book a meeting with Dr. Joshua Klopper, Veracyte’s Medical Director for Endocrinology. We’ll be here through Tuesday and look forward to connecting with you in Boston. https://lnkd.in/eKWxzuE6 #ThyroidCancer #Endocrinology #ENDO2024

Hello from the 2024 ASCO Annual Meeting! The Veracyte team is thrilled to be in Chicago and looks forward to connecting with others at the meeting – join us at booth 35131 to learn more about how we're transforming cancer care worldwide. #ASCO24 

A new clinical validation study published in European Urology highlights the potential of a whole-genome sequencing approach to revolutionize minimal residual disease (#MRD) detection in patients with muscle invasive bladder cancer. Developed by C2i Genomics, which was recently acquired by Veracyte, this innovative MRD method can help pave the way for more personalized and effective care for patients. Learn more about how this technology can transform MRD assessment and improve patient outcomes. https://lnkd.in/g994q5C9

On #WorldThyroidDay, we celebrate the strides made in personalizing diagnosis and treatment for thyroid nodules. For years, indeterminate thyroid nodules posed a significant challenge, often leading to unnecessary surgeries. At Veracyte, we are committed to driving innovation in this space, empowering clinicians with comprehensive insights to make more accurate treatment decisions, and helping patients navigate thyroid nodule diagnosis. #ThyroidCancer #endocrinology